Abstract
In guidelines, a combination therapy of two or more antihypertensives is recommended for treatment of hypertension where monotherapy is ineffective. Although diuretics or calcium channel blockers are commonly used as add-ons to angiotensin receptor blocker (ARB), the most effective and safe combination has not been established. In this randomized 4-month study, the efficacy and safety were compared between an ARB/diuretics (losartan/hydrochlorothiazide [HCTZ]) combination and the most prescribed combination, ARB/calcium channel blocker (candesartan/amlodipine) in hypertensive patients for whom 8 mg/day of candesartan proved ineffective. After 36 patients were recruited and allocated into two groups, changes in blood pressure (BP) and laboratory values were analyzed in 31 patients: 16 patients received losartan (50 mg/day)/HCTZ (12.5 mg/day) (L/H group), and 15 patients received candesartan (8 mg/day)/amlodipine (5 mg/day) (C/A group) after 5 patients were withdrawn. After 4 months, L/H significantly (p<0.001) reduced mean systolic BP (SBP)/diastolic BP (DBP) from baseline 160/89±13/11 mmHg to 140/80±9/8 mmHg, and C/A reduced BP from 161/90±10/11 mmHg to 141/79±10/7 mmHg. The efficacy in reducing BP was similar between the two combination therapies. L/H significantly reduced serum potassium, but within the normal range, and did not increase serum uric acid or serum triglyceride. With L/H, the percentage of patients who attained the BP goal in SBP was higher in elderly patients than in younger patients. As L/H is more cost-effective than candesartan/amlodipine and has fewer adverse effects on uric acid and other metabolic parameters than diuretic monotherapy, it is concluded to be useful for the management of hypertension.
Similar content being viewed by others
Article PDF
References
Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Japanese Society of Hypertension : Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Laragh JH : Abstract, closing summary, and table of contents for Laragh's 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens 2001; 14: 1173–1177.
Kim-Mitsuyama S, Izumi Y, Izumiya Y, Yoshida K, Yoshiyama M, Iwao H : Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res 2004; 27: 771–779.
Suzuki J, Iwai M, Li Z, et al: Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E–deficient mice. J Hypertens 2005; 23: 1383–1389.
Mancia G, Seravalle G, Grassi G : Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens 2003; 16: 1066–1073.
Mori H, Ukai H, Yamamoto H, et al: Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143–151.
MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS : Losartan and low-dose HCTZ in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–285.
Dahlof B, Lindholm LH, Carney S, Pentikainen PJ, Ostergren J, LOA Study Group: Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. J Hypertens 1997; 15: 1327–1335.
Menard J : Critical assessment of combination therapy development. Blood Press Suppl 1993; 1: 5–9.
Carlsen JE, Kober L, Torp-Pedersen C, Johansen P : Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975–978.
Jounela AJ, Lilja M, Lumme J, et al: Relation between low dose of HCTZ, antihypertensive effect and adverse effects. Blood Press 1994; 3: 231–235.
MacKenney JM, Goodman RP, Wright JT Jr, Rifai N, Aycock DG, King ME : The effect of low-dose hydrochlorothiazide on blood pressure, serum potasium, and lipoproteins. Pharmacotherapy 1986; 6: 179–184.
Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB : Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension 1992; 19 ( 2 Suppl): II26–II29.
Nakashima M, Uematsu T, Kosuge K, Kanamaru M : Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333–335.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shimosawa, T., Gohchi, K., Yatomi, Y. et al. Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine. Hypertens Res 30, 831–837 (2007). https://doi.org/10.1291/hypres.30.831
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.831
Keywords
This article is cited by
-
The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis
International Urology and Nephrology (2018)
-
Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study
Clinical and Experimental Nephrology (2015)
-
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial
Hypertension Research (2012)
-
Hydrochlorothiazide Versus Calcium Channel Blockers: What is the Best Add-on to a Renin-Angiotensin System Blocker for Treating Hypertension in Patients with Renal Disease?
Current Hypertension Reports (2011)
-
One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors
Hypertension Research (2010)